Exocan Healthcare is at the forefront of utilizing exosome technologies for cancer diagnosis and drug discovery, focusing on the development of innovative platforms that enhance precision medicine. Their approach leverages the unique properties of exosomes—nano-sized vesicles that provide critical insights into the genetic makeup and growth patterns of cancer cells—allowing for non-invasive diagnostics. By capturing highly pure exosomes and their biomolecules, Exocan aims to facilitate biomarker discovery and improve personalized treatment strategies. Their commitment to advancing exosome research is evident in their development of patented technologies that enable tumor heterogeneity mapping and early cancer detection.

In addition to diagnostic applications, Exocan is pioneering drug discovery methods through the use of microenvironment-competent three-dimensional tumor models. These models support high-throughput screening and repositioning of drugs, enhancing the efficiency of the drug discovery process. Furthermore, Exocan is innovating in drug delivery by engineering exosomes to target specific tumor characteristics, thereby improving therapeutic outcomes. Overall, Exocan Healthcare is dedicated to harnessing the potential of exosomes in oncology, creating a comprehensive suite of technologies that bridge the gap between research and clinical application.

India

ExoCan Healthcare Ltd is a clinical stage company developing exosome based liquid biopsy tests. We are one of the first few exosome companies globally and India's first exosome company established in 2015. ExoCan developed a patented exosome workflow which is world's fastest, and most efficient.  We are committed to bring change in cancer precision medicine with our ever growing portfolio of  exosome technologies.

Exocan Healthcare

Company Details